Antisense Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Antisense Therapeutics Stock Forecast and Price Target
According to experts, who recently provided their 2024 price targets for Antisense Therapeutics, the average price target is $0.25, with a high estimate of $0.27 and a low estimate of $0.23. That is a potential upside of approximately 212.5% from the last closing price of $0.08 on May, 2024. If you're interested in ANP stock, it's important to compare it to other companies in the industry.
212.50% Upside
Antisense Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
Antisense Therapeutics's Price has grown in the last four years, jumping from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach $0.08 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CU6 Stock Forecast | Clarity Pharmaceuticals Ltd | Buy |
2
|
$3.27 | Buy/Sell | $2.00 | -4.59% |
| MYX Stock Forecast | Mayne Pharma Group | Buy |
11
|
$7.01 | Buy/Sell | $3.90 | 0.43% |
| PBP Stock Forecast | Probiotec | Hold |
17
|
$2.83 | Buy/Sell | $3.15 | 6.01% |
| VLS Stock Forecast | Vita Life Sciences | - |
0
|
$2.27 | Buy/Sell | $0.85 | -100.00% |
| IXHL Stock Forecast | Incannex Healthcare | - |
6
|
$2.55 | Buy/Sell | $73.15 | -100.00% |
Antisense Therapeutics Revenue Forecast for 2023 - 2025 - 2030
Antisense Therapeutics's Revenue has grown in the last three years, jumping from $670.00k to $1.58M – an increase of 135.82%. In the following year, 0 experts forecast that Antisense Therapeutics's Revenue will decrease by 13.08%, to $1.37M. In 2030, professionals predict that Antisense Therapeutics's Revenue will decrease by 14.31%, to $1.35M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PAA Stock Forecast | PharmAust | - |
5
|
$0.22 | Buy/Sell | $0.00 | -100.00% |
| MVP Stock Forecast | Medical Developments Internati... |
9
|
$0.45 | Buy/Sell | $1.60 | 573.33% | |
| LGP Stock Forecast | Little Green Pharma Ltd | Hold |
7
|
$0.13 | Buy/Sell | $0.28 | 30.77% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IDT Stock Forecast | IDT Australia | - |
0
|
$0.11 | Buy/Sell | $0.00 | -100.00% |
| CAN Stock Forecast | Cann Group | - |
0
|
$0.06 | Buy/Sell | $1.12 | -100.00% |
| KZIA Stock Forecast | Kazia Therapeutics |
6
|
$0.35 | Buy/Sell | $0.30 | -48.57% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EOF Stock Forecast | Ecofibre | - |
6
|
$0.07 | Buy/Sell | $1.14 | -100.00% |
| SNT Stock Forecast | Syntara |
2
|
$0.02 | Buy/Sell | $0.34 | 900.00% | |
| ACR Stock Forecast | Acrux |
0
|
$0.07 | Buy/Sell | $0.25 | 257.14% |
Antisense Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
Antisense Therapeutics's EBITDA has increased by 96.16% In the last three years, going from $-5.99M to $-11.75M. In the next year, analysts expect EBITDA to reach $-13.72M – an increase of 16.77%. For the next seven years, the forecast is for EBITDA to grow by 100.29%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IXC Stock Forecast | Invex Therapeutics Ltd | - |
0
|
$0.08 | Buy/Sell | $0.00 | -100.00% |
| AGH Stock Forecast | Althea Group Holdings | - |
6
|
$0.04 | Buy/Sell | $0.00 | -100.00% |
| EMD Stock Forecast | Emyria | - |
0
|
$0.05 | Buy/Sell | $0.18 | -100.00% |
Antisense Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Antisense Therapeutics's EBIT has grown, increasing from $-6.00M to $-11.77M – a growth of 96.17%. The next year looks promising for Antisense Therapeutics, with analysts predicting EBIT of $-13.80M – an increase of 17.25%. Over the next seven years, experts anticipate that Antisense Therapeutics's EBIT will grow at a rate of 100.23%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BXN Stock Forecast | Bioxyne | - |
0
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| MDC Stock Forecast | Medlab Clinical | - |
0
|
$6.60 | Buy/Sell | $18.84 | -100.00% |
| AVE Stock Forecast | Avecho Biotechnology | - |
0
|
$0.00 | Buy/Sell | $0.09 | 0.00% |
Antisense Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
Antisense Therapeutics's EPS has grown in the last four years, jumping from $-0.01 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach $-0.02 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZLD Stock Forecast | Zelira Therapeutics | - |
4
|
$0.72 | Buy/Sell | $11.70 | -100.00% |
| CCO Stock Forecast | The Calmer Co International | - |
-14
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| CGB Stock Forecast | Cann Global | - |
0
|
$0.02 | Buy/Sell | $0.00 | -100.00% |
Site Navigation
.jpg)